A new study in interventional psychiatry research is examining whether a single day of treatment could rapidly reduce symptoms of postpartum depression. Published in The Journal of Clinical Psychiatry, the Phase 2a trial evaluated inhaled mebufotenin, also known as 5-MeO-DMT, in women with moderate-to-severe postpartum depression.
The preliminary findings are notable for both the speed and magnitude of symptom improvement. However, the study was small, open-label, and lacked a control group, making larger controlled trials essential before conclusions can be drawn about clinical effectiveness.
Why Faster Treatment For Postpartum Depression Matters
Postpartum depression can affect maternal functioning, family relationships, and child development. Standard antidepressants such as selective serotonin reuptake inhibitors remain an important treatment option, but their therapeutic effects may take several weeks to emerge. The study authors also point to zuranolone, an FDA-approved treatment specifically for postpartum depression, which is administered as a 14-day oral treatment course.
These limitations have increased interest in treatments capable of producing meaningful improvement more quickly, particularly for patients experiencing substantial symptoms during a critical period of maternal and infant health.
Testing Inhaled Mebufotenin For Postpartum Depression
Researchers enrolled 10 women between ages 18 and 45 who had major depressive disorder with peripartum onset and moderate-to-severe symptoms. Participants received GH001, a synthetic inhaled formulation of mebufotenin, using an individualized regimen of up to three escalating doses of 6, 12, and 18 mg during a single treatment day.
The study did not include a planned psychotherapeutic intervention before, during, or after administration. Participants were monitored by healthcare professionals and could be discharged on the same day once they met predefined readiness criteria.
Depression Scores Fell Within Hours
The primary outcome was the change in Montgomery-Åsberg Depression Rating Scale, or MADRS, scores from baseline through Day 8.
Participants entered the study with an average MADRS score of 36.7. By Day 8, the average score had fallen by 35.4 points, representing an approximately 96% reduction from baseline. All 10 participants met criteria for both treatment response and remission at the two-hour post-dose assessment, Day 2, and Day 8.
Maternal functioning also improved. Among the eight participants with available Barkin Index of Maternal Functioning data, scores increased by an average of 34.1 points by Day 8, corresponding to an approximately 56% improvement.
A Short Psychoactive Window Could Influence Treatment Delivery
Mebufotenin acts as a nonselective serotonin receptor agonist with greater affinity for the 5-HT1A receptor than the 5-HT2A receptor. The researchers suggest that its effects on serotonergic and glutamatergic signaling and neuroplasticity could contribute to the rapid antidepressant response observed in the trial.
The psychoactive effects were also relatively brief. Median effects following individual doses lasted approximately 22 to 25 minutes, depending on dose. This short duration could distinguish inhaled mebufotenin from psychedelic interventions requiring substantially longer supervised treatment sessions.
Safety Findings Add Another Important Signal
Eight of the 10 participants experienced treatment-emergent adverse events, but most were mild. Headache was the most frequently reported event, and researchers reported no serious or severe treatment-emergent adverse events. Temporary increases in blood pressure and heart rate occurred after administration and returned to baseline without intervention.
All participants were considered ready for discharge on the treatment day.
The researchers also conducted exploratory breast milk analyses in four lactating participants. Mebufotenin concentrations declined rapidly, with levels below quantification by Days 2 and 8. These observations are preliminary and should not be interpreted as establishing breastfeeding safety or clinical guidance.
Promising Results Require Controlled Confirmation
The study provides an unusually strong early signal, but its design places clear limits on interpretation. Only 10 participants were enrolled, follow-up lasted one week, and there was no blinded comparison group. The study population was also predominantly White, and most participants were not taking pharmacotherapy for their current depressive episode.
The trial was sponsored by GH Research Ireland Limited, and several authors reported employment, stock ownership, consulting relationships, or other financial connections involving the company.
Still, the findings establish a compelling direction for further investigation. If rapid improvement can be reproduced in larger randomized controlled trials and maintained over longer follow-up periods, inhaled mebufotenin could represent a distinctly different treatment model for postpartum depression, centered on brief supervised administration rather than continuous daily medication.
Citations
- Johnson M, Aceves Baldo P, Arbe E, et al. “Inhaled Mebufotenin (GH001) for Adult Patients With Postpartum Depression: A Phase 2a Open-Label Clinical Trial.” The Journal of Clinical Psychiatry. 2026;87(3):25m16284. DOI: 10.4088/JCP.25m16284.
PubMed Article - ClinicalTrials.gov. “Phase 2 Clinical Trial of GH001 in Postpartum Depression.” NCT05804708. U.S. National Library of Medicine.
ClinicalTrials.gov Study Record
Explore more at Interventional Psychiatry Network
